Uncategorized

Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data

Published

3 weeks ago

on

Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version